San Jose, CA – July 7, 2008 - AnaSpec, one of the world’s largest providers of catalog peptides, has introduced its latest series of PAR peptides.
Protease or Proteinase-Activated Receptors, PARs, belong to the seven transmembrane G-protein coupled family of receptors.1 These receptors are activated when the amino terminus of the receptor is cleaved by specific serine proteases - thrombin (PAR-1, 3 and 4) and trypsin (PAR-2). 2 The cleaved amino end can then act as a tethered ligand on the second extracellular loop of the receptor thereby activating the receptor. 1 Short sequences contained in the amino terminus have been found to activate the receptors on their own, without the need for the protease cleavage.
PAR Peptide Series:
PAR-1 Agonist, STAL – 2, amide
Sequence: SFLLRN-NH2
PAR-1 Agonist, Thrombin Receptor Activator for Peptide 6 (TRAP - 6)
Sequence: SFLLRN
Scrambled PAR-1 Agonist
Sequence: FSLLRN-NH2
Thrombin Receptor (42 - 48) Agonist, human
Sequence: SFLLRNP
Thrombin Receptor Agonist, amide
Sequence: SFLLR-NH2
Thrombin Receptor Agonist
Sequence: SFLLR
Thrombin Receptor Antagonist
Sequence: FLLRN
SFLLRNPNDKYEPF, TRAP-14, Thrombin Receptor 42 - 55, human
Sequence: SFLLRNPNDKYEPF
PAR - 1 Agonist
Sequence: TFLLRN
PAR - 1 Agonist, amide
Sequence: TFLLRN-NH2
PAR - 1 Agonist, amide
Sequence: TFLLRNPNDK-NH2
Protease - Activated Receptor - 2, PAR - 2 Agonist, amide
Sequence: SLIGKV-NH2
PAR - 3 Agonist, amide
Sequence: SFNGGP-NH2
PAR - 1 Agonist, amide
Sequence: TFLLRNPNDK-NH2
Protease - Activated Receptor - 4, PAR - 4 Agonist, amide, human
Sequence: GYPGQV-NH2
Protease - Activated Receptor - 4, PAR - 4 Agonist, amide, murine
Sequence: GYPGKF-NH2
N - 10 Region of TRAP
Sequence: DEIKYSEEVC
Company Info
AnaSpec, Inc. is a leading provider of integrated proteomics solutions to pharmaceutical, biotech, and academic research institutions throughout the world. With a vision for innovation through synergy, AnaSpec focuses on three core technologies: peptides, detection reagents (dyes, assay kits, & antibodies), and combinatorial chemistry. For more information, visit www.anaspec.com
References:
1. Macfarlane, SR. et al. Pharmacol. Rev. 53, 245 (2001).
2. Santulli, RJ. et al. PNAS 92, 9151 (1995).
